Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Terminated 39Completed 10Withdrawn 3Suspended 1

Sponsor Class

NIH 6OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 1Genitourinary 1CNS 1

Conditions

Waldenstrom Macroglobulinemia 1Recurrence 1Prostatic Neoplasms 1Optic Nerve Glioma 1

Interventions

Radiotherapy 91pembrolizumab 88Cyclophosphamide 84Gemcitabine 70Cisplatin 70Magnetic Resonance Spectroscopy 65Carboplatin 60Radiosurgery 55Paclitaxel 55Nivolumab 48Dexamethasone 45Bevacizumab 42Biopsy 41Fluorouracil 39durvalumab 37Surveys and Questionnaires 36Docetaxel 36fludarabine 35Doxorubicin 35Radiation 33Oxaliplatin 33Capecitabine 33Rituximab 32fludarabine phosphate 31Leucovorin 31Cytarabine 30Melphalan 29Etoposide 28Pemetrexed 27Irinotecan 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × OTHER × antineoplaston A10 × Clear all
NCT00003512 2018-02-05

Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia

Burzynski Research Institute

Phase 2 Withdrawn
Lymphoid

Waldenstrom Macroglobulinemia

NCT00003534 2018-01-31

Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer

Burzynski Research Institute

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT01260103 2017-07-26

Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma

Burzynski Research Institute

Phase 3 Withdrawn
CNS

Recurrence, Optic Nerve Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡